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MDR1 gene–related clonal selection and P-glycoprotein function and expression
in relapsed or refractory acute myeloid leukemia
Marry M. van den Heuvel-Eibrink, Erik A. C. Wiemer, Marjan J. de Boevere, Bronno van der Holt, Paula J. M. Vossebeld,
Rob Pieters, and Pieter Sonneveld
The expression of P-glycoprotein (P-
gp), encoded by the MDR1 gene, is an
independent adverse prognostic factor
for response and survival in de novo
acute myeloid leukemia (AML). Little is
known about MDR1 expression during
the development of disease. The present
study investigated whether MDR1 gene–
related clonal selection occurs in the
development from diagnosis to relapsed
AML, using a genetic polymorphism of
the MDR1 gene at position 2677. Expres-
sion and function of P-gp were studied
using monoclonal antibodies MRK16 and
UIC2 and the Rhodamine 123 retention
assay with or without PSC 833. No differ-
ence was found in the levels of P-gp
function and expression between diagno-
sis and relapse in purified paired blast
samples from 30 patients with AML. Thir-
teen patients were homozygous for the
genetic polymorphism of MDR1 (n 5 7 for
guanine, n 5 6 for thymidine), whereas 17
patients were heterozygous (GT). In the
heterozygous patients, no selective loss
of one allele was observed at relapse.
Homozygosity for the MDR1 gene (GG or
TT) was associated with shorter relapse-
free intervals (P 5 .002) and poor survival
rates (P 5 .02), compared with heterozy-
gous patients. No difference was found in
P-gp expression or function in patients
with AML with either of the allelic variants
of the MDR1 gene. It was concluded that
P-gp function or expression is not up-
regulated at relapse/refractory disease
and expression of one of the allelic vari-
ants is not associated with altered P-gp
expression or function in AML, consis-
tent with the fact that MDR1 gene–related
clonal selection does not occur when
AML evolves to recurrent disease. (Blood.
2001;97:3605-3611)
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Introduction
Classic multidrug resistance (MDR) encoded by the MDR1 gene is
characterized by expression of P-glycoprotein (P-gp), which acts as
a drug efflux pump in the plasma membrane. Expression of MDR1
has been identified as an independent adverse prognostic factor for
complete remission (CR) and survival in patients with acute
myeloid leukemia (AML), especially in adults.1-11 Little is known
about possible changes in MDR1 gene expression during the
development to relapse or refractory disease, especially in paired
analyses of clinical samples of patients with AML. It is conceivable
that MDR1 positive clones develop by clonal selection during
chemotherapy or by MDR1 gene activation. This phenomenon has
been described for Burkitt lymphoma, in which single allelic
MDR1 expression was found to be up-regulated during the
development of disease.12
In the present study, we investigated whether clonal selection of
one MDR1 allele contributes to drug resistance in AML, by
studying the genetic polymorphism of the MDR1 gene at position
2677.13 This study was performed in paired samples of patients
with AML at time of diagnosis and at first relapse or refractory
disease. In addition, an analysis was performed of the expression
and function of P-gp. To the best of our knowledge, no previous
studies have been reported in which the P-gp levels were measured
in the allelic variants of the MDR1 gene.
Patients and methods
Patients
Bone marrow samples from 30 patients with AML (9 children, 21 adults)
were obtained from the iliac crest at diagnosis and at time of first relapse
(n 5 27) or refractory disease (n 5 3) (Table 1). Written informed consent
was obtained from each patient and/or their parents to perform these
studies. AML classification, according to the French-American-British
(FAB) criteria14 was M1 (n 5 8), M2 (n 5 11), M4 (n 5 2), M5 (n 5 7),
and M6 (n 5 2). Cytogenetic analysis was carried out by standard
techniques, and the findings were described according to the international
nomenclature.15 Patients with a deletion or loss of chromosome 7 were not
included in the study, because of the (possible) loss of one MDR1 gene
which is located on 7q21.1, which complicates the analysis of polymor-
phism in these patients. All patients were treated according to the Helsinki
agreement and were included in treatment protocols of the Dutch-Belgian
Hemato-Oncology Collaborative Group (protocol HOVON 4/4a resp.
HOVON 29) for young adults (n 5 17), European Organisation for
Research and Treatment of Cancer (EORTC protocol LAM 9) (n 5 1) for
patients 60 years or older, and the Dutch Childhood Leukemia Study Group
(DCLSG: protocol ANLL 87 and 94) (n 5 9) for children (younger than 18
years old). After relapse or in case of refractory disease after induction
therapy, adults were treated according to the HOVON 30 protocol. The
pediatric patients received treatment according to institutional protocols
(Table 2). For some patients, individual therapy choices were made (Table 1). CR
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status was defined as normocellular marrow with , 5% blasts in a bone
marrow (BM) smear and normal peripheral blood cell counts.
Methods
Patient samples. Bone marrow aspirates were obtained in heparinized
tubes. Mononuclear bone marrow cells (MNCs) were collected by Ficoll
Hypaque density gradient centrifugation (density 1.077g/m3) (Pharmacia,
Uppsala, Sweden). To obtain purified samples with more than 85% blasts,
T-cell depletion and adherence depletion were performed.16 Cells were
cryopreserved in Iscoves modified Dulbecco medium (IMDM; Gibco,
Paisley, United Kingdom) supplemented with 10% dimethyl sulfoxide
(DMSO; Merck, Darmstadt, Germany) and 20% fetal calf serum (FCS;
Gibco) and stored in liquid nitrogen. On the day of the experiments bone
marrow cells were thawed. For flowcytometry experiments, cells were
washed and resuspended in IMDM supplemented with 10% FCS and
gentamycin at a concentration of 4 3 106 cells/mL. Total RNA was isolated
using Trisolv extraction (Biotecx, Houston, TX).
Oligonucleotide hybridization and dotblot analysis. Both DNA and
RNA were used as templates in the polymerase chain reaction (PCR). One
microgram of genomic DNA was used as a template in the PCR for 40
cycles to investigate the genetic polymorphism at the DNA level. One
microgram of total RNA was reverse transcribed and the cDNA template
was subjected to 40 cycles of PCR. The following primers were used as
described by Mickley12,13: 59 2521 GCAAATCTTGGGACAGGAAT;
Table 1. Clinical characteristics of 30 patients with acute myeloid leukemia
Patient
Expression of MDR1
gene polymorphism
(G/T variant)
Diagnosis Relapse/Refractory disese
Age
(years)
FAB
classification Karyotype
Relapse free
after 1st CR
(months)
Treatment
(at time of relapse/
refractory disease)
Response
(to reinduction)
1 GT 2 M5 Unfavorable 8 NT
2 G 1 M6 Neutral 4 2cdA/Ara-C/Idarubicin No CR
3 GT 47 M2 Neutral 50 HOVON30 CR
4 T 55 M2 Neutral — HOVON30 No CR**
5 T 50 M5 Neutral 25 HOVON30 CR
6 GT 50 M2 Neutral 7 HOVON30 CR
7 GT 62 M1 Unfavorable 31 HOVON30 CR
8 GT 61 M1 Neutral 29 HOVON30 No CR
9 GT 35 M1 Favorable 12 HOVON30 CR
10 GT 9 M5 Unfavorable 9 NT
11 GT 12 M1 Neutral 33 DCLSG ANLL94 CR
12 GT 37 M1 Neutral 12 HOVON29 CR
13 GT 57 M4 Neutral 4 NT
14 G 46 M5a Neutral 6 NT
15 GT 67 M2 Neutral 9 EORTC 9 No CR
16 T 16 M4eo Favorable 8 HOVON29 CR
17 GT 19 M5a Neutral 28 HOVON29 No CR
18 GT 42 M2 Neutral 11 HOVON29 CR
19 GT 1 M1 Neutral 14 DCLSG ANLL87 No CR
20 G 41 M6 Neutral 4 HOVON30 CR
21 GT 10 M2 Favorable 58 DCLSG ANLL94 CR
22 T 63 M2 Neutral 20 NT
23 G 1 M5 Unfavorable 10 DCLSG ANLL87 No CR
24 GT 27 M2 Neutral 14 HOVON30 CR
25 G 34 M5 Neutral — HOVON30 No CR**
26 GT 5 M1 Neutral 18 DCLSG ANLL87 CR
27 G 18 M2 Neutral 8 Mitoxantrone No CR
28 T 55 M1 Neutral — HOVON30 No CR**
29 T 49 M2 Neutral 6 NT
30 G 67 M2 Neutral 5 HOVON30 No CR
CR indicates complete remission after 1 or 2 courses of reinduction chemotherapy; No CR, refractory disease at time of relapse, No CR** indicates never CR after
diagnosis; NT, not treated for relapse. For karyotypes, unfavorable indicates t(9;22), 11q23 with MLL rearrangements, complex karyotype, 5q-; favorable indicates inv(16),
t(15;17) and t(8;21); and neutral indicates normal and other karyotypes.
Table 2. Cumulative drug doses in the treatment protocols for acute myeloid leukemia
Drug Ara-C DNR Adria Amsa Ida VP16 Mitox Pred 6TG VCR CP CsA
Induction
HOVON 4/4A 13 400 135 360 500 50
HOVON 29 13 400 360 36 500 50
DCLSG ANLL87* 22 400 180 120 1050 1120 2580 6 1000
DCLSG ANLL94* 33 400 120 36 950 20 1120 2520 6 1000
Reinduction
EORTC 9 6000 90 50
HOVON 30 500 50 65 mg/kg
(Total cumulative dose in mg/m2.) Ara-C indicates cytosine arabinoside; Adria, adriamycin; DNR, daunorubicin; Amsa, amsacrine; Ida, idarubicin; VP16, etoposide; Mitox,
mitoxantrone; Pred, prednisolone; 6TG, 6-thioguanine; VCR, vincristine; CP, cyclophosphamide; and CsA, cyclosporin A.
*Indicates 1 53 intrathecal Ara-C.
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39 RNA, 2796 CTCCTTTCGTGTGTAGAAAC; 39, DNA,2681CCTTC2687
CACTCAGTTTGATTT.
Reverse transcriptase treatment preceded amplification in order to
evaluate RNA expression. All PCR experiments included controls without
DNA or RNA. After amplification of 1 mg template, 30% of the PCR
product was loaded in each of 2 adjacent wells of a slot-blot apparatus. The
Zeta Probe nylon filter (Biorad, Hercules, CA) was cut out into 2 halves and
each half was hybridized with a different oligonucleotide. Two 19-bp
allele-specific oligonucleotide probes (HMO7 and HMO8) were 59-
phosphorylated with [g32P]-ATP and T4 polynucleotide kinase. HMO7 and
HMO8 cover residues 2667 to 2685 and were used for hybridizations.
HMO7 possessess a G at position 2677 and HMO8 contains a T at the same
position. Internal controls for hybridization and specificity were included in
all experiments. For this purpose, two 30-bp oligonucleotides, designated
HMC3 and HMC4, were used. These oligonucleotides cover residues 2656
to 2685 of the MDR1 gene with HMC3 possessing a G at position 2677 and
HMC4 a T at the same position. Equal amounts of each control were spotted
on both sides of the filter. Because the hybridizations were performed under
identical conditions, with probes labeled to similar specific activities, the
signals from the control oligonucleotides were similar. For quantification of
the hybridization spots, the blots were exposed to a Phosfor Imager screen
(Molecular Dynamics, Sunnyvale, CA).
Expression of P-glycoprotein. For measurement of the expression of
P-gp, cells were incubated at room temperature with the monoclonal
anti–P-gp antibodies MRK1617 (Kamiya Biomedical, Tukwila, WA) at a
concentration of 10 mg/mL and also, in separate tubes, with UIC218
(Immunotech, Marseille, France) at a concentration of 12.5 mg/mL or with
an isotype-matched mIgG2a control antibody (Sigma, St Louis, MO) at a
concentration of 10 mg/mL. Cell-bound antibodies were detected by
fluorescein isothiocyanate (FITC)–labeled rabbit antimouse immunoglobu-
lin antibodies (Dako, Glostrup, Denmark). Results are given as the ratio of
the mean fluorescence of cells incubated with the anti–P-gp antibody
divided by the mean fluorescence of cells incubated with the control
mIgG2a antibody. To measure the expression of P-gp in CD34-positive
cells, cells were labeled with phyco-erythrin-Cy5–labeled CD34 antibody
or a phycoerythrin-Cy5–labeled matched mIgG1 antibody (Immunotech).
Function of P-glycoprotein. For measurement of the function of P-gp,
the fluorescent molecule Rhodamine 123 (Rho 123) (Sigma) was used as a
P-gp substrate.19,20 Cells were incubated for 1 hour at 37°C at 5% CO2 in the
absence or presence of 2 mM of the P-gp modulator PSC 833 (Novartis,
Basel, Switzerland). After this incubation, 200 ng/mL Rho 123 was added
to the cells. A sample was taken at t 5 0 minutes to correct for background
fluorescence and at t 5 75 minutes to measure intracellular Rho 123
retention. Results were calculated as the PSC/Rho 123 retention ratio of the
mean intracellular Rho 123 fluorescence of cells exposed to PSC 833
divided by the mean intracellular Rho 123 fluorescence of cells not exposed
to PSC 833. As controls, the drug-sensitive human myeloma cell line 8226
S and the drug-resistant P-gp expressing variant 8226 D6 cells21 were
included in each experiment. Taking all experiments together, the mean
ratio of P-gp function of the negative control cell line 8226 S was
0.91 6 0.07 (mean 6 SD). The mean ratio of P-gp function of the positive
control cell line 8226 D6 was 7.03 6 4.69 (mean 6 SD).
For analysis of the function of P-gp in CD34-positive cells, cells were
labeled with phyco-erythrin-Cy5–labeled CD34 antibody or as a control
phycoerythrin-Cy5–labeled mIgG1 antibody (Immunotech). Fluorescence
was measured using a FACScalibur flowcytometer (Becton Dickinson, San
Jose´, CA). Cells were incubated with 0.1 mM TO-PRO-3 (Molecular
Probes, Eugene, OR) to exclude nonviable cells in the fuctional and
expression studies.
Statistical analysis. Expression and functional levels of P-gp, either at
diagnosis or at relapse or refractory disease, were compared between
subgroups using the Mann-Whitney test in case of 2 subgroups, and the
Kruskal-Wallis test in case of 3 subgroups. Moreover, MDR1 expression at
relapse or refractory disease was compared with that at diagnosis using the
Wilcoxon matched-pairs signed-ranks test, which was restricted to patients
with data available both at diagnosis and at relapse or refractory disease. All
P values are 2-sided and a significance level a 5 .05 was used.
Results
Thirty patients with AML were studied at diagnosis and during the
course of their disease. Twenty-seven patients developed a relapse
after reaching CR with induction chemotherapy. Three patients
were primary refractory to induction chemotherapy (Table 1).
Oligonucleotide hybridization and dotblot analysis
Oligonucleotide hybridization studies of position 2677 of the
MDR1 gene revealed 7 patients with a G variant, 6 patients with a T
variant, and 17 patients with a GT variant. The 17 patients with
heterozygous expression at diagnosis also showed GT expression
at relapse. In these patients, no up-regulation of either allele was
noticed during the development of disease at RNA level. Conse-
quently, in this group of patients no evidence of a MDR1
gene–associated selection of a resistant clone was found.
P-glycoprotein expression and function
MRK16 expression (n 5 27) and UIC2 expression (n 5 25) re-
vealed no differences in P-gp expression at relapse or refractory
disease as compared with diagnosis (P 5 .14 and P 5 .22, respec-
tively) (Table 3). No difference of MRK16 expression in the
CD34-positive subpopulation was found (n 5 11) (P 5 1.0) in the
paired analysis. The analysis of UIC2/CD34 in matched pairs
showed a trend to a lower expression level (P 5 .07) in relapsed/
refractory disease as compared with diagnosis, although the
number of patients that could be analyzed for UIC2/CD34 was
Table 3. Paired analysis of P-glycoprotein expression and function in patients
with acute myeloid leukemia at diagnosis and relapse/refractory disease
At
diagnosis
At relapse and/or
refractory disease P value
MDR1
MRK16
Median 2.16 1.83 .14
Range 1.22-7.65 1.02-5.55
N 27
MRK16/CD341
Median 2.77 2.28 1.00
Range 1.52-9.27 1.46-9.6
N 11
UIC2
Median 2.37 1.74 .22
Range 1.47-12.3 0.99-6.39
N 25
UIC2/CD341
Median 3.5 2.42 .07
Range 1.51-26.6 0.86-7.34
N 8
PSC/Rho
Median 1.13 1.10 .26
Range 0.87-2.11 0.81-2.19
N 27
PSC/Rho/CD341
Median 1.43 1.22 .39
Range 0.98-2.7 0.82-3.26
N 12
For P-gp expression, the monoclonal antibodies MRK 16 and UIC2 were used;
for P-gp function, the PSC/Rho 123 retention ratio was used. In samples with greater
than 10% CD34 expression, the variables were also evaluated in the CD341
subfraction of the blasts. The P values indicate the differences between diagnosis
and relapse/refractory disease.
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small (n 5 8) (Table 3; Figure 1C). The CD34 expression was not
different at relapse as compared to diagnosis (P 5 .31).
The PSC/Rho 123 retention ratio (n 5 27) was not significantly
different between diagnosis and relapsed/refractory AML (P 5 .26).
When analyzed in the CD34-positive subpopulation of blasts
(n 5 12), comparable results were found (P 5 .39) (Table 3;
Figure 1A). No difference was found in P-gp expression (P 5 .67
for MRK16 expression, P 5 .82 for UIC2 expression) or PSC/Rho
ratio (P 5 .09) at diagnosis nor at relapse/refractory disease
(P values of .42, .67, and .11, respectively) between adults
and children.
P-glycoprotein versus MDR1 allelic expression
As the functional meaning of the genetic polymorphism of the
MDR1 gene has not been established as yet, we analyzed P-gp in
patients with expression of the G, T, and GT variants. The median
MRK16 expression ratio was not significantly different in the
various allelic variants (P 5 .72 at diagnosis and P 5 .34 at
relapse). Also, no difference was found with monoclonal antibody
UIC2 (P 5 .81 at diagnosis and P 5 .25 at relapse) and the
PSC/Rho 123 retention ratio (P 5 .26 at diagnosis, P 5 .11 at
relapse). No difference was found in P-gp expression or function
when homozygous patients were compared with heterozygous
patients (Table 4). Similarly, in the CD34-positive fraction we did
not find differences in P-gp expression and function between the
different MDR1 allelic variants at diagnosis nor at relapse and/or
refractory disease. The results show that there is no difference in
P-gp expression and function in AML blast cells between the
different specific allelic variants of the MDR1 gene. The therapeu-
tic outcome of patients with the different allelic variants showed a
significant difference, that is, homozygosity was associated with a
Figure 1. P-glycoprotein expression and function in the CD34-positive popula-
tion of the paired AML patients. (C) The UIC2 and (B) MRK16 ratios represent the
expression of P-gp, and (A) PSC 833/Rho123 represents the function of P-gp. Dx
indicates diagnosis; Rel/RD, relapsed/refractory AML. The dotted lines indicate the
median values.
Figure 2. Survival of the patients with AML. Distinguishing patients that are
homozygous (GG and TT) from patients that are heterozygous (GT) for the genetic
polymorphism of position 2677 of the MDR1 gene. (A) Time from diagnosis until
relapse/refractory disease. (B) Overall survival from relapse/refractory disease. N
indicates number of patients investigated; O, observed events.
Table 4. Analysis of P-glycoprotein expression and function in the
homozygous vs the heterozygous allelic variants of the MDR1 gene
at time of relapse/refractory disease
GG or TT GT P value
MDR1
MRK16
Median 1.54 2.14 .15
Range 1.02-5.45 1.18-5.55
N 13 17
MRK16/CD34
Median 1.88 2.68 .22
Range 1.49-4.90 1.46-9.6
N 7 7
UIC2
Median 1.56 2.28 .22
Range 1.12-6.39 0.99-5.24
N 13 17
UIC2/CD34
Median 1.67 2.72 .10
Range 0.86-7.34 1.69-5.15
N 7 8
PSC/Rho
Median 1.08 1.14 .30
Range 0.81-1.85 0.84-2.19
N 13 17
PSC/Rho/CD34
Median 1.21 1.42 .40
Range 1.07-1.72 0.82-3.26
N 9 9
For P-gp expression, the monoclonal antibodies MRK16 and UIC2 were used; for
P-gp function, the PSC/Rho 123 retention ratio was used. In samples with more than
10% CD34 expression, the variables were also evaluated in the CD341 subfraction of
the blasts. The P values indicate the differences between the homozygous and
heterozygous patients.
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shorter time from diagnosis to relapse (P 5 .002) and a shorter
overall survival from relapse (P 5 .02) (Figure 2A,B).
Discussion
Clinical resistance to chemotherapy is a major problem in relapsed
and/or refractory AML. MDR1 expression in de novo AML is an
adverse prognostic factor for CR and survival.3-7,11,22 It is conceiv-
able that up-regulation of the MDR1 gene is involved in the
development of relapse and/or refractory disease, although this has
not been investigated in paired analyses of respectable numbers of
clinical samples of patients with AML.12 In the present study we
analyzed whether clonal selection associated with the MDR1 gene
is involved in the development of relapsed AML. This is the first
study that examined the allelic expression of MDR1 in AML, using
the genetic polymorphism of the MDR1 gene. Our data show that
there is no evidence of a MDR1 gene–related clonal selection in the
evolution of AML to relapse or refractory disease.
This is consistent with our observation that P-gp expression and
function did not increase from diagnosis to relapsed/refractory
state. Several studies have reported a higher MDR1 expression at
time of relapse as compared to diagnosis.23-29 However, most
studies compared patients who were not matched and studies in
paired patient samples are scarce and generally they were per-
formed in small numbers of patients. Most studies suggest an
identical expression or even lower level of MDR1 in relapsed/
refractory AML.29-32 Only the sequential analysis by Wood, who
used immunocytochemistry techniques, showed a higher percent-
age of P-gp–positive samples in 14 relapsed patients with AML as
compared with diagnosis.33 In pediatric patients, only 3 case
reports are available.25,34,35 Therefore, although many studies have
suggested that MDR1 is up-regulated in relapsed and/or refractory
AML, sequential studies do not support this theory (Table 5 and
Table 6). The present analysis, which is the largest paired study in
AML thus far, is an attempt to quantify MDR1 expression at
genomic and protein level during the development toward resistant
disease. In the 9 children and 21 adults studied, we did not find
evidence that MDR1, although being a strong prognostic factor at
the time of diagnosis, is up-regulated at time of relapse and/or
refractory disease in AML. We suggest that similar sequential
studies of other mechanisms of drug resistance should be per-
formed in patients with AML during the course of their disease in
order to determine which drug resistance proteins are associated
with clonal selection at relapse. In these studies it will be important
to analyze children and younger adults separately from elderly
patients with AML, since different mechanisms might be important
in different age groups.6 Until now, the only study that analyzed
P-gp expression in a large group of children with AML showed that
in contrast to adult AML, MDR1 expression was not of prognostic
significance.39 In the present study no difference was found in P-gp
expression and function between adults and children.
Our study emphasizes that it is important to study MDR1
expression in clinical samples from patients with AML. In many
cell lines, including even AML cell lines, MDR expression may be
up-regulated as a direct response of cells to antineoplastic drugs.
Table 6. Review of MDR1 expression in acute myeloid leukemia in nonpaired studies
Author Reference
Number of patients Expression
level Age category
MDR1 expression in
relapsed vs de novo AMLDx Relapse
Beck 36 14 23 RNA Children Higher
Guerci 26 69 10 Protein Adults Higher
List 29 21 29 Protein Adults Equal/lower
Marie 24 21 6 RNA Adults Equal
Musto 23 8 7 Protein Adults Lower
Maslak 27 18 19 Protein Adults and children Higher
Michieli 28 38 21 Protein Adults Higher
Table 5. Review of analyses of MDR1 expression in paired samples of patients with acute myeloid leukemia
Author Reference
Number
of patients
Expression
level MDR1
Age
category
MDR1 expression
number in relapsed
vs de novo AML
Gekeler 35 1 RNA Children Higher
Beck 36 1 RNA Children Higher
Guerci 26 4 Protein Adults Higher/equal
Hart 32 9 RNA Adults Higher/lower
Ino 31 21 Protein Adults Equal/lower
Sato 37 6 RNA Adults Equal
Ito 30 10 DNA Adults Equal
Ito 30 1 RNA Adults Equal
Ito 30 10 Protein Adults Higher/lower
Kaczorowski 34 1 Protein Children Higher
List 29 17 Protein Adults Lower
Marie 24 4 RNA Adults Higher/equal
Marie 38 4 RNA Adults Higher/lower/equal
Ma 41 2 Protein Adults Higher/equal
Musto 23 2 Protein Adults Higher
Maslak 27 5 Protein Adults Higher
Michieli 28 7 Protein Adults Higher/lower/equal
Wood 33 14 Protein Adults Higher
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However, it seems apparent that this does not occur in patients with
AML.40-48 This is the first analysis of the functional significance of
the genetic polymorphism of MDR1 in highly purified samples of
AML. P-gp function and expression were similar in any one of the
specific allelic variants (G, T, and GT). These findings suggest that
the genetic polymorphism of the MDR1 gene (at position 2677)
lacks functional importance in AML. However, we found that
patients with homozygous expression of the MDR1 gene (GG or
TT) had a shorter time to relapse and overall survival from
relapse/refractory disease than heterozygous patients. This finding
warrants further studies on the role of genetic polymorphisms of
MDR1 in AML.
MDR1 expression at diagnosis is a strong adverse prognostic
factor in AML. However, our sequential analysis reveals that there
is no higher function or expression of P-gp at relapse or refractory
disease, and that specific allelic expression is not related to
increased P-gp expression or function. Since no loss of a specific
MDR1 allele has been observed in these patients with AML, MDR1
gene–related clonal selection plays no role in the development of
resistant disease. These data suggest that mechanisms other than
MDR1 might be responsible for the development of clinical
resistance in these patients.
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